Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

213 results about "Hsp90 inhibitor" patented technology

An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. Furthermore, a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers. Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as semisynthetic derivatives 17-N-Allylamino-17-demethoxygeldanamycin (17AAG).

Novobiocin Analogues Having Modified Sugar Moieties

Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.
Owner:UNIVERSITY OF KANSAS

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.
Owner:CONFORMAL THERAPEUTICS CORP (US)

Hsp90 inhibitors, methods of making and uses therefor

InactiveUS20060205705A1Increasing Raf- degradationBiocideSugar derivativesDiseaseGeldanamycin
The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and / or the amelioration of symptoms of cancer and other proliferative tissue disorders.
Owner:UNIV OF COLORADO THE REGENTS OF

Compositions and methods involving MDA-7 for the treatment of cancer

The present invention concerns methods and compositions involving MDA-7 protein or an MDA-7-encoding nucleic acid in combination with either 1) a COX-2 selective inhibitor, such as celecoxib, 2) an Hsp90 inhibitor, such as geldanamycin, or a geldanamycin derivative or analog, 3) a vitamin E compound, for the treatment of cancer, 4) a TNF, such as TNF-alpha, 5) a VEGF inhibitor, or 6) an inhibitor of IL-10. In certain examples, a treatment for breast cancer is provided. In other examples a treatment for lung cancer is provided. Such examples involve, in some cases, an adenovirus vector that expresses MDA-7 protein.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

HSP90 Inhibitors Containing a Zinc Binding Moiety

InactiveUS20080234297A1Enhanced and unexpected propertyEffective for treating diseaseBiocideOrganic chemistryHsp InhibitorZinc binding
The present invention relates to HSP90 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.
Owner:CURIS INC

Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors

The present invention provides a method for treating cancer. The method involves the administration of an HSP90 inhibitor and an enzyme inhibitor, where the combined administration provides a synergistic effect. In one aspect of the invention, a method of treating cancer is provided where a subject is treated with a dose of an HSP90 inhibitor in one step and a dose of an enzyme inhibitor in another step. In another aspect of the invention, a method of treating cancer is provided where a subject is first treated with a dose of an HSP90 inhibitor and subsequently treated with a dose of an enzyme inhibitor. In another aspect of the invention, a method of treating cancer is provided where a subject is first treated with a dose of an enzyme inhibitor and subsequently treated with a dose of an HSP90 inhibitor.
Owner:KOSAN BIOSCI

Fused amino pyridine as hsp90 inhibitors

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
Owner:CURIS INC

Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants

The present invention provides a method for treating cancer. The method involves the administration of an HSP90 inhibitor and an immunosuppressant, where the combined administration provides a synergistic effect. In one aspect of the invention, a method of treating cancer is provided where a subject is treated with a dose of an HSP90 inhibitor in one step and a dose of an immunosuppressant in another step. In another aspect of the invention, a method of treating cancer is provided where a subject is first treated with a dose of an HSP90 inhibitor and subsequently treated with a dose of an immunosuppressant. In another aspect of the invention, a method of treating cancer is provided where a subject is first treated with a dose of an immunosuppressant and subsequently treated with a dose of an HSP90 inhibitor.
Owner:KOSAN BIOSCI

Small-Molecule Hsp90 Inhibitors

Hsp90 inhibitors are provided having the formula:with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO2. alkyl, COO-alkyl, KH2, OH, CN, SO2X5, NO2, NO, C═SR2 NSO2X5, C═OR2, where X5 is F, NH2, alkyl or H, and R2 is alkyl, NH2, NH-alkyl or O-alkyl, C1 to C6 alkyl or alkoxy; or wherein X1 has the formula -0-(CH2)n-0-, wherein n is an integer from O to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5′-position and the other at the 4′-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.
Owner:SLOAN KETTERING INST FOR CANCER RES

Targeted therapeutics

InactiveUS20140079636A1Facilitate additiveFacilitate synergisticBiocideOrganic chemistryBiological targetCytotoxicity
The present invention provides pharmacological compounds including an effector moiety conjugated to an binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
Owner:SYNTA PHARMA CORP

HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients

Provided is a method for treating non-small cell lung cancer with wild-type EGFR gene and / or KRAS gene by administering to a subject in need thereof, an effective amount of a triazolone compound according to the following formula:a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein.
Owner:SYNTA PHARMA CORP

Small-molecule Hsp90 Inhibitors

Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
Owner:SLOAN KETTERING INST FOR CANCER RES

Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors

InactiveUS7211562B2Avoid or reduce their respective toxicity to patientsGrowth inhibitionHeavy metal active ingredientsPeptide/protein ingredientsBinding siteRadicicol
The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.
Owner:SLOAN KETTERING INST FOR CANCER RES

Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor

InactiveUS20130171105A1Increasing side effect profileSurprising biological activityBiocideHeavy metal active ingredientsDiseasePharmaceutical drug
A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
Owner:SYNTA PHARMA CORP

Novobiocin analogues having modified sugar moieties

The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.
Owner:UNIVERSITY OF KANSAS

Novobiocin analogues having modified sugar moieties

Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.
Owner:UNIVERSITY OF KANSAS

Methods and compositions for treating Toxoplasma

This invention relates to a method for treatment of latent Toxoplasma gondii infection. The invention provides for the use of Hsp90 inhibitors for treatment of latent Toxoplasma gondii infection, particularly in an immunocompromised subject. Also provided is a screening method for identifying compounds useful for treating latent Toxoplasma gondii infection.
Owner:UNIVERSITY OF VERMONT

Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors

The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.
Owner:SLOAN KETTERING INST FOR CANCER RES

Uses of labeled hsp90 inhibitors

The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).
Owner:SLOAN KETTERING INST FOR CANCER RES +1

Methods for Sensitizing Cancer Cells to Inhibitors

The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies. In general, the heat shock protein inhibitors of the present invention share a common structure, namely a 2H-benzo[a]quinolizine tricyclic ring. Also encompassed are methods for a high throughput screen to identify heat shock inhibitors that sensitize cancer cells to anti-cancer therapies.
Owner:TRUSTEES OF BOSTON UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products